Humulin M3 Kwikpen (Insulin Human (Rdna))

Humulin M3 Kwikpen is indicated for the management of hyperglycemia in adults with diabetes.

• Type 1 diabetes mellitus, used as basal insulin in a multiple‑daily‑injection regimen.
• Type 2 diabetes mellitus, used when basal insulin is required in addition to oral agents.
• Situations where a rapid‑acting insulin is needed to control post‑prandial glucose spikes.
• Use in combination with other insulin preparations to achieve a basal‑bolus therapy.
• Adjusted for patients transitioning from other rapid‑acting insulin products.

• Insulin human binds to the insulin receptor on cell membranes, activating the intrinsic tyrosine kinase activity of the receptor. This triggers downstream signaling through the PI3‑K/Akt pathway, promoting translocation of GLUT‑4 transporters to the cell surface and increasing glucose uptake in muscle and adipose tissue. It also suppresses hepatic gluconeogenesis, thereby lowering circulating glucose concentrations and improves glycogen synthesis in liver.

Adverse reactions reported with Humulin M3 Kwikpen are generally consistent with other rapid‑acting insulins and can be grouped by frequency.

Common

• Hypoglycemia, especially if meals are delayed or carbohydrate intake is insufficient.
• Injection‑site reactions such as redness, swelling, or itching.
• Lipodystrophy, including lipohypertrophy at repeated injection sites.
• Weight gain associated with improved glycemic control.

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures.
• Allergic reactions ranging from urticaria to anaphylaxis.

When prescribing or using Humulin M3 Kwikpen, clinicians and patients should consider several safety precautions.

• Assess renal and hepatic function, as impairment may alter insulin requirements.
• Monitor blood glucose regularly to avoid hypoglycemia, especially during dose changes.
• Educate patients on proper injection technique and rotating sites to prevent lipodystrophy.
• Use caution in pregnancy and lactation; benefits should outweigh potential risks.
• Review concomitant medications that affect glucose metabolism, such as glucocorticoids or beta‑blockers.
• Store the pen at controlled room temperature and discard after the indicated in‑use period.

Humulin M3 Kwikpen may interact with other drugs that influence blood glucose levels or insulin action.

Avoid

• Concurrent use of other rapid‑acting insulins without dose adjustment.
• MAO‑B inhibitors that can potentiate hypoglycemia.

Use with caution

• Beta‑blockers, which may mask hypoglycemia symptoms.
• Corticosteroids, which can increase insulin resistance.
• Thiazide diuretics, which may raise blood glucose.
• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that also lower glucose.
• Alcohol, which can cause delayed hypoglycemia.